Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.
It is "not a material loss", DBS analyst Sachin Mittal...